AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04162327
Drug: IBI315
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive IBI315 RP2D until disease progression,intolerability, informed consent withdraw, or otherreasons leading to treatment discontinue.
Trial: NCT03958721
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1,000 mg/m2 twice daily taken by mouth every other week
Trial: NCT03178864
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accepted standard of care as per American Heart Association/American Stroke Association Guidelines (initial use of unfractionated heparin or low-molecular weight heparin with transition to an oral vitamin K antagonist or continuation with low-molecular weight heparin) with choice of agent at the treating physician's discretion.
Trial: NCT04037605
Drug: Cosyntropin Injectable Product
RxNorm normalized name: cosyntropin Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cosyntropin injection is given twice per inpatient visit
Trial: NCT04037605
Drug: Hydrocortisone Injection (also known as solu-cortef)
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone IV push is given twice per inpatient visit
Trial: NCT04037605
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for Ketoconazole are given 4 times per inpatient visit
Trial: NCT04037605
Drug: Saline solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline Solution (placebo) for ganirelix subcutaneous injection
Trial: NCT00216060
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral placebo combined with androgen deprivation
Trial: NCT00391534
Drug: modified release formulation of oxcarbazepine (OXC MR)
RxNorm normalized name: oxcarbazepine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC MR. Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
Trial: NCT00391534
Drug: immediate release formulation of oxcarbazepine (OXC IR)
RxNorm normalized name: oxcarbazepine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC IR (divided in two daily doses). Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
Trial: NCT00003204
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00357539
Drug: Azithromycin (T1225)
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03398681
Drug: Ferric carboymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric Carboxymaltose solution \[Ferinject® (FCM), Vifor Pharma (Glattbrugg, Switzerland)\]
Trial: NCT02000973
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia combined with thoracic epidural 0.9% normal saline
Trial: NCT03921086
Drug: Antihypertensive medication according to the study's algorithm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with stage 1 hypertension will receive monotherapy and risks of hypotension are negligible. A single antihypertensive lowers blood pressure (BP) on average by 10/5 mmHg.~Patients with stage 2 hypertension will be initiated on two medications and this is recommended by all international hypertension guidelines and studies have shown prompt BP control with minimal side effects.~For borderline patients, the investigators will elect to not treat them for blood pressure ranges of BP: 135-140/85-90 mmHg and give them a letter on discharge to be followed up at their local clinic. The letter will detail that they are potentially hypertensive patients and need to be followed up closely in future.~Patients with Stage 3 hypertension will be referred to the in-hospital physician as per the algorithm.
Trial: NCT03138889
Drug: NKTR-214
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NKTR-214: The dose will be 0.008 mg/kg intravenous (IV) infusion administered over 30 (± 5) minutes q3w. The maximum dose of NKTR-214 will be 0.012 mg/kg. This will include a fixed 3+3 dose escalation followed by intra-patient step-up dose escalation based on tolerability.
Trial: NCT03138889
Drug: NKTR-214
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NKTR-214: The dose will be 0.006 mg/kg intravenous (IV) infusion.
Trial: NCT03138889
Drug: NKTR-214
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NKTR-214: The dose will be 0.010 mg/kg intravenous (IV) infusion.
Trial: NCT01438957
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02634684
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) and completes approximately 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
Trial: NCT03924154
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive pill manufactured to mimic RVT-1201 600 mg immediate-release tablet
Trial: NCT03395886
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The noninvasive ventilation intolerated patients was sedated by remifentanil.
Trial: NCT01053728
Drug: SAR161271
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Solution for injection~Route of administration: subcutaneous
Trial: NCT01514812
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03787953
Drug: Anti-PD-1/PD-L1 antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study is a real-world study. According to the actual medical history of patients, the usage of anti-PD-1/PD-L1 antibodies was collected.
Trial: NCT02989675
Drug: 10% dextrose
RxNorm normalized name: Aminosyn II 4.25% in 10% Dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus of 10% dextrose 5mls/kg
Trial: NCT02562430
Drug: Welbutrin XL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5% of participants will receive Welbutrin XL in phase 1 of the study.
Trial: NCT02562430
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 87.5% of subjects will be randomized to placebo in phase 1 of the study.
Trial: NCT02050360
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04893941
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02386761
Drug: Single Ascending Dose (SAD)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02386761
Drug: Multiple Ascending Dose (MAD)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03203642
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Tablet (identical to tesevatinib); Route of administration: orally
Trial: NCT03358901
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04626297
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given SC
Trial: NCT00656539
Drug: AzaSite®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for \~26 days
Trial: NCT02300987
Drug: LEE011
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02300987
Drug: LEE011 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00762411
Drug: LY450139
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally once daily.
Trial: NCT00762411
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally once daily.
Trial: NCT00003387
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01541215
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (s.c., under the skin) once daily for 26 weeks. Subjects will discontinue placebo treatment in the open-labelled extension. Rescue treatment will be allowed if rescue criteria are met.
Trial: NCT02302716
Drug: LY2963016
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT02302716
Drug: Oral Antihyperglycemic Medication
RxNorm normalized name: ANTIHYPOGLYCEMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as per standard-of-care.
Trial: NCT03561558
Drug: Ibuprofen D
RxNorm normalized name: Ibuprofen Dye Free
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen D, oral suspension, 200 mg / 5ml, manufactured by LLC Pharmtechnology, Belarus
Trial: NCT03561558
Drug: Nurofen® for Children
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurofen® for Children, Oral Suspension, 100 mg / 5 ml, marketed by Reckitt Benckiser Healthcare International Ltd, UK
Trial: NCT03712202
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03878264
Drug: CORT118335 Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CORT118335 900 mg spray-dried dispersion in bottle and vehicle for oral administration
Trial: NCT02090933
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01481779
Drug: LY2605541
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by SC injection with a pen device.
Trial: NCT04158440
Drug: 4cycles(Placebo + platinum-based doublet chemotherapy)+13 cycles(Placebo )
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological: Placebo by IV infusion every 3 weeks (Q3W), given on cycle day 1;Drug: Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1;Drug: Corboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;Drug: Pemetrexed 500 mg/m\^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.Drug:Paclitaxel 175 mg/m\^2 by IV infusion Q3W;Drug:Docetaxel 60-75 mg/m\^2 by IV infusion Q3W
Trial: NCT00721916
Drug: SOL(The combination therapy of S-1, Leucovorin, and Oxaliplatin)
RxNorm normalized name: (S)-Leucovorin
DrugBank: (6R)-Folinic acid (DB03256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-OHP 85 mg/m2 iv. for 2 hr on day 1 of each 2 weeks cycle S-1 40-60 mg bid day 1～day 7 LV 25 mg bid day 1～day 7
Trial: NCT00297141
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: chemotherapy oral use
Trial: NCT02899312
Drug: PSMA PET/CT scan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will undergo the same procedures listed in Detailed Description in the protocol section.
Trial: NCT02274558
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NBI-98854 placebo capsules
Trial: NCT01113801
Drug: LY2382770
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection given monthly for 12 months
Trial: NCT01113801
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection given monthly for 12 months
Trial: NCT00999284
Drug: ZK200775
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 0.3 mg/kg/h of ZK200775 over a period of 4 hours.
Trial: NCT00999284
Drug: ZK200775
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 0.75 mg/kg/h of ZK200775 over a period of 4 hours.
Trial: NCT03278158
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in the placebo arm will receive a single oral tablet containing no active drug.
Trial: NCT01949051
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal aqueous 0 mcg microsuspension supplied in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension
Trial: NCT00973050
Drug: Casodex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg Tabelt
Trial: NCT01279915
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01550640
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bolus of remifentanil 1 µg/kg will be given 30 sec before induction to general anesthesia
Trial: NCT00695110
Drug: Oral testosterone undecanoate (TU) (300 mg T equivalents/dose)
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three capsules each containing 100 mg testosterone (T) as TU, BID. 300 mg T equivalents BID 30 minutes after initiation of breakfast and dinner meals for 7 days. A 7-14 day washout period occurred between successive Treatment Periods.
Trial: NCT00695110
Drug: Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (400 mg T equivalents/dose)
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two capsules each containing 100 mg T as TU and 100 mg T as TE, BID. 400 mg T equivalents BID 30 minutes after initiation of breakfast and dinner meals for 7 days. A 7-14 day washout period occurred between successive Treatment Periods.
Trial: NCT00695110
Drug: Oral testosterone undecanoate (TU) (200 mg T equivalents/dose with and without food)
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two capsules each containing 100 mg T as TU, BID for 8 days. 200 mg T equivalents BID 30 minutes after initiation of meals (breakfast and dinner), except for Day 8 when the morning dose was administered fasting. A 7-14 day washout period occurred between successive Treatment Periods.
Trial: NCT00695110
Drug: Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (300 mg T equivalents/dose)
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two capsules each containing 150 mg T as TU and 150 mg T as TE, BID. 300 mg T equivalents BID 30 minutes after initiation of breakfast and dinner meals for 7 days.
Trial: NCT01632449
Drug: Test product
RxNorm normalized name: Patch test product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimethyl Fumarate (BG00012)
Trial: NCT01632449
Drug: Reference product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimethyl Fumarate (BG00012)
Trial: NCT01898611
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline will be used as a placebo
Trial: NCT01936688
Drug: MK-3222 200 mg
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-3222 200 mg administered SC.
Trial: NCT01936688
Drug: MK-3222 100 mg
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-3222 100 mg administered SC.
Trial: NCT01936688
Drug: Placebo to MK-3222
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to MK-3222 administered SC.
Trial: NCT01366560
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT03852355
Drug: Radiofrequency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ), received bilateral 3rd occipital nerve RF under fluoroscopic guidance. Levobupivacaine (0.3 mL; 0.75%) and triamcilonone (1 mg) were injected at each level
Trial: NCT03852355
Drug: Steroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: received systemic steroids oral prednisolone tablet, 10 mg/day
Trial: NCT03741179
Drug: ASA-withdrawn group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients whith sFlt/PlGF ratio \< 38 at 24+0-27+6 weeks will be randomized into two arms of the trial. Patients allocated in the experimental arm will stop the ASA treatment.
Trial: NCT02592785
Drug: BAY1163877
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1: Single dose 600 mg on day 1, no drug on day 2 and then twice daily administration of the same dose for the remaining 19 days of cycle 1. From cycle 2 onwards all subjects are continuously treated for 21 days per cycle with twice daily administration of the same dose.~Cohort 2: Single dose 800 mg on day 1, no drug on day 2 and then twice daily administration of the same dose for the remaining 19 days of cycle 1. From cycle 2 onwards all subjects are continuously treated for 21 days per cycle with twice daily administration of the same dose.
Trial: NCT02504008
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly for 6 weeks
Trial: NCT03645876
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m2
Trial: NCT02647853
Drug: TAT4 Gel concentration A
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02647853
Drug: TAT4 Gel concentration B
RxNorm normalized name: benzocaine Oral Gel [Zilactin B]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02647853
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02550548
Drug: Ex-9 infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ex-9 infusion will be initiated at start of hyperglycemic clamp (target: 125 mg/dL)
Trial: NCT01835067
Drug: C3F8 Gas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravitreal injection of 0.3 mls C3F8
Trial: NCT00514150
Drug: normal saline 0.9%
RxNorm normalized name: BD Posiflush Normal Saline 0.9% Prefilled Syringe Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV 154 mEq/L solution of NaCl 0.9% (infused at the rate of 3 ml/kg/ hour one hour before the angiographic procedure, continuing at the rate of 1 ml/kg/ hour for 6 hours after the procedure. Maximum rate of fluid permitted is that for a body weight of 110 Kg.)
Trial: NCT03904836
Drug: Tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 5 milligrams per kilogram intravenous for one dose
Trial: NCT03486938
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablet
Trial: NCT03486938
Drug: AGB101 220 mg tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 220 mg AGB101 active compound
Trial: NCT02320149
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching sarecycline tablets taken orally at the same time each day.
Trial: NCT00560079
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00190996
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00539331
Drug: AZD2171
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT03210376
Drug: Deep Neuromuscular Blockade (NMB)
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep Neuromuscular Blockade (NMB) given during surgery.
Trial: NCT03210376
Drug: Moderate Neuromuscular Blockade (NMB)
RxNorm normalized name: Blockade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate Neuromuscular Blockade (NMB) given during surgery.
Trial: NCT02812147
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Added as described in the Arm/Group Descriptions.dded as described in the Arm/Group Descriptions.
Trial: NCT02348606
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01083329
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obese subjects will receive nicotinic acid or placebo for 16 weeks
Trial: NCT01624389
Drug: F18-AV45
RxNorm normalized name: fluorodeoxyglucose F18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study will recruit a total of 200 evaluable subjects (50 cognitively normal volunteers, 100 MCI, and 50 AD, respectively) Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.~Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events.
Trial: NCT01840501
Drug: Placebo (single dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered subcutaneously (an injection under the skin) as a single dose in Part 1.
Trial: NCT01840501
Drug: Placebo (multiple doses)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered subcutaneously (an injection under the skin) once daily for 10 days in Part 2.